Background: This study investigates the effectiveness of extracorporeal shock wave (ECSW) in ameliorating inflammatory mediator expression and neointimal formation in a rat model of vascular injury. Methods and Results: Male Sprague-Dawley rats with left carotid artery (LCA) injury induced by balloon dilatation (BD; group 1) were compared with group 2 [LCA injury plus ECSW-181 (defined as 181 total shocks given in LCA at 0.011 mJ/mm2) on day 2 post-LCA injury], and group 3 (normal controls). The rats in each group were further divided into 3 subgroups (n = 6, each) that were sacrificed on postoperative day 3, 7 and 14, respectively. The results demonstrated that, compared to groups 2 and 3, group 1 had significantly increased cellular expression of CD40, interleukin-18, and connexin 43 at each analyzed time point (all p < 0.001). Additionally, LCCA macrophage (CD68) recruitment was substantially increased in group 1 compared to groups 2 and 3 (all p < 0.001). Furthermore, LCA neointimal proliferation and media thickness were markedly higher in group 1 than in groups 2 and 3 on days 7 and 14 post-BD (all p < 0.001). Conclusions: ECSW markedly attenuates inflammatory responses, proliferation of neointima and smooth muscle cells in a rat vascular injury model.

Keywords:
Vascular injury, Inflammatory mediators, Neointimal proliferation, Shock wave therapy
1.
Murray GJL, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–1442.
2.
Murray GJL, Lopez AD: Mortality by cause for eight regions of the word: Global Burden of Disease Study. Lancet 1997;349:1269–1276.
3.
Braunwald E: Shattuck lecture – cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360–1369.
4.
Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115–126.
5.
Van der Wall AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36–44.
6.
Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, Fu Morgan: Levels and values of serum high-sensitivity C-reactive protein within 6 h after the onset of acute myocardial infarction. Chest 2004;126:1417–1422.
7.
Yip HK, Wu CJ, Yang CH, Chang HW, Fang CY, Hung WC, Hang CL: Serial changes in circulating concentrations of soluble CD40 ligand and C-reactive protein in patients with unstable angina undergoing coronary stenting: role of inflammatory mediators in predicting late restenosis. Circ J 2005;69:890–895.
8.
Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276–1282.
9.
Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R: Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002;105:2019–2023.
10.
Remskar M, Li H, Chyu KY, Shah PK, Cercek B: Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. Circ Res 2001;88:390–394.
11.
Maffia P, Grassia G, Di Meglio P, Carnuccio R, Berrino L, Garside P, Ianaro A, Ialenti A: Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury. Circulation 2006;114:430–437.
12.
Chadjichristos CE, Matter CM, Roth I, Sutter E, Pelli G, Lüscher TF, Chanson M, Kwak BR: Reduced connexin43 expression limits neointima formation after balloon distension injury in hypercholesterolemic mice. Circulation 2006;113:2835–2843.
13.
Selzman CH, Meldrum DR, Cain BS, Meng X, Shames BD, Ao L, Harken AH: Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation. J Surg Res 1998;80:352–356.
14.
Honda HM, Leitinger N, Frankel M, Goldhaber JI, Natarajan R, Nadler JL, Weiss JN, Berliner JA: Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol 1999;19:680–686.
15.
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK: Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60–68.
16.
Tedgui A, Mallat Z: Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001;88:877–887.
17.
Ogden JA, Toth-Kischkat A, Schultheiss R: Principles of shock wave therapy. Clin Orthop Relat Res 2001;387:8–17.
18.
Ciampa AR, de Prati AC, Amelio E, Cavalieri E, Persichini T, Colasanti M, Musci G, Marlinghaus E, Suzuki H, Mariotto S: Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. FEBS Lett 2005;579:6839–6845.
19.
Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, Matsumoto Y, Kajihara N, Eto M, Matsuda T, Yasui H, Takeshita A, Sunagawa K: Extracorporeal cardiac shock wave therapy markedly ameliorates ischemic-induced myocardial dysfunction in pigs in vivo. Circulation 2004;110:3055–3061.
20.
Gutersohn A, Caspari G: Shock waves upregulate vascular endothelial growth factor m-RNA in human umbilical vascular endothelial cells. Circulation 2000;102(suppl):18.
21.
Yip HK, Chang LT, Sun CK, Youssef AA, Sheu JJ, Wang CJ: Shock wave therapy applied to rat bone marrow-derived mononuclear cells enhance formation of cells stained positive for CD31 and vascular endothelial growth factor. Circ J 2008;72:150–156.
22.
Rompe D, Zoellner J, Nafe B: Shock wave therapy versus conventional surgery in the treatment of calcifying tendinitis of the shoulder. Clin Orthop 2001;387:78–82.
23.
Rompe JD, Decking J, Schoellner C, Nafe B: Shock wave application for chronic plantar fasciitis in running athletes: a prospective, randomized, placebo-controlled trial. Am J Sports Med 2003;31:268–275.
24.
Wang CJ, Huang HY, Pai CH: Shock wave therapy enhanced neovascularization at the tendon-bone junction: an experiment in dogs. J Foot Ankle Surg 2002;41:16–22.
25.
Wang CJ, Wang FS, Yang KD, Weng LH, Hsu CC, Huang CS, Yang LC: Shock wave therapy induces neovascularization at the tendon-bone junction. A study in the rabbits. J Orthop Res 2003;21:984–998.
26.
Lin FY, Chen YH, Tasi JS, Chen JW, Yang TL, Wang HJ, Li CY, Chen YL, Lin SJ: Endotoxin induces toll-like receptor 4 expression in vascular smooth muscle cells via NADPH oxidase activation and mitogen-activated protein kinase signal pathways. Arterioscler Thromb Vasc Biol 2006;26:2630–2637.
27.
Mulvihill NT, Foley JB: Inflammation in acute coronary syndromes. Heart 2002;87:201–204.
28.
Chadjichristos CE, Matter CM, Roth I, Sutter E, Pelli G, Lüscher TF, Chanson M, Kwak BR: Reduced connexin43 expression limits neointima formation after balloon distension injury in hypercholesterolemic mice. Circulation 2006;113:2835–2843.
29.
Li JM, Singh MJ, Itani M, Vasiliu C, Hendricks G, Baker SP, Hale JE, Rohrer MJ, Cutler BS, Nelson PR: Recombinant human thrombomodulin inhibits arterial neointimal hyperplasia balloon injury. J Vasc Surg 2004;39:1074–1083.
30.
Linde A, Mosier D, Blecha F, Melgarejo T: Innate immunity and inflammation – new frontiers in comparative cardiovascular pathology. Cardiovasc Res 2007;73:26–36.
31.
Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54:17c–23c.
32.
Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A: Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001;89:E41–E45.
33.
Whitman SC, Ravisankar P, Daugherty A: Interleukin-18 enhances atherosclerosis in apolipoprotein E (–/–) mice through release of interferon-gamma. Circ Res 2002;90:E34–E38.
34.
Mallat Z, Corbaz A, Scoazec A, Besnard S, Lesèche G, Chvatchko Y, Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598–1603.
35.
Hirsch AT, Criqui MC, Treat-Jacobson D: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–1324.
36.
Ouriel K: Peripheral arterial disease. Lancet 2001;358:1257–1264.
37.
Blackburn JP, Peter NS, Yeh HI, Rothery S, Green CR, Severs NJ: Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1219–1228.
38.
Yeh HI, Lupu F, Dupont E, Severs NJ: Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Aterioscler Thromb Vasc Biol 1997;17:3174–3184.
39.
Davis TA, Stojadinovic A, Anam K, Amare M, Naik S, Peoples GE, Tadaki D, Elster EA: Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. Int Wound J 2009;6:11–21.
40.
Mariotto S, Cavalieri E, Amelio E, Ciampa AR, de Prati AC, Marlinghaus E, Russo S, Suzuki H: Extracorporeal shock waves: from lithotripsy to anti-inflammatory action by NO production. Nitric Oxide 2005;12:89–96.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.